NCT03524326 - Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2018

Primary Completion Date

October 13, 2022

Study Completion Date

October 13, 2022

Conditions

Head and Neck Squamous Cell CarcinomaCutaneous Squamous Cell CarcinomaHead and Neck CancerHead and Neck Carcinoma

Interventions

DRUG

Lenvatinib Pill

24 mg oral daily

DRUG

Lenvatinib Pill

20 mg oral daily

DRUG

Lenvatinib Pill

14 mg oral daily

DRUG

Cetuximab

400mg/m2 IV, then 500mg/m2 IV weekly

DRUG

Lenvatinib Pill

10 mg oral daily

DRUG

Lenvatinib Pill

4 mg oral daily

Trial Locations (7)

10021

Memorial Sloan - Kettering Cancer Center, New York

10604

Memoral Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Cancer Center @ Commack, Commack

07920

Memoral Sloan Kettering Basking Ridge, Basking Ridge

07748

Memoral Sloan Kettering Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale

All Listed Sponsors

lead

Memorial Sloan Kettering Cancer Center

OTHER